Nexentis Technologies Inc. (NXTS): R&D Expense
$179.0K
Year ended 2025-12-31
$798.0K
Trailing 12 months to 2026-06-30
-38.5%
3-year compound annual growth
-15.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $179.0K | -51.5% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $369.0K | -81.0% | 2025-03-31, From 2024-01-01 |
| 2023-12-31 | $1.94M | +151.4% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $770.8K | +43.1% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $538.7K | +29.2% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $417.0K | -32.3% | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | $615.6K | +72.4% | 2021-03-29, From 2019-01-01 |
| 2018-12-31 | $357.1K | n/a | 2020-03-30, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $179.0K | -51.5% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $9.80M | +172.1% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $10.75M | -16.6% |
| Evofem Biosciences, Inc. (EVFM) | 2024-12-31 | $1.84M | -37.2% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $813.0K | -12.3% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $121.1K | -32.5% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $25.22M | +26.1% |
| Propanc Biopharma, Inc. (PPCB) | 2025-06-30 | $223.7K | -9.8% |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | $14.29M | -60.9% |
Compare NXTS, QNRX, IXHL, EVFM side by side · Screen every company in Pharmaceutical Preparations ↗